Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
Dose/route boundary: a single 300 mg oral dose of radiolabeled citicoline was studied in healthy adults, within the page’s 250-500 mg amount but not its repeated daily schedule.
The absorption, metabolism and excretion of cytidine diphosphate choline (CDP-choline, citicoline, Somazina) were investigated in six adult healthy subjects after a single oral dose of 300 mg of the 14C-labelled compound.
Pharmacokinetics of 14C CDP-choline. Arzneimittel-Forschung · 1983 · PMID 6412727
Evidence scope. Human pharmacokinetic study in six healthy adults; single oral radiolabeled dose only.
Dose/frequency boundary: 500 mg/day citicoline for 12 weeks was studied in healthy older adults with age-associated memory impairment.
Participants were randomized to receive placebo (n = 51) or citicoline (n = 49; 500 mg/d) for 12 wk.
Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. The Journal of nutrition · 2021 · PMID 33978188
Evidence scope. Human randomized double-blind trial; dietary supplementation in adults aged 50-85 years. The abstract does not separately spell out capsule/tablet formulation in the quoted sentence.
Mechanism: orally administered citicoline is absorbed as choline and cytidine and supports phosphatidylcholine/membrane-lipid synthesis.
Upon oral or parenteral administration, CDP-choline releases its two principle components, cytidine and choline.
CDP-choline: pharmacological and clinical review. Methods and findings in experimental and clinical pharmacology · 1995 · PMID 8709678
Evidence scope. Pharmacological and clinical review spanning oral and parenteral use; mechanism-level statement, not a dose-specific efficacy claim.
Safety boundary: a single 300 mg oral dose was well tolerated by six healthy adult subjects.
The compound was well tolerated by the subjects.
Pharmacokinetics of 14C CDP-choline. Arzneimittel-Forschung · 1983 · PMID 6412727
Evidence scope. Very small healthy-volunteer pharmacokinetic study; single exposure only, insufficient for broad long-term safety.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Exact full frequency range: 250-500 mg orally 1-2 times daily. Checked abstracts support a single 300 mg oral exposure and a 500 mg/day supplementation regimen, but not the full 250-500 mg once- or twice-daily schedule.